nodes	percent_of_prediction	percent_of_DWPC	metapath
Gadoversetamide—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000648	0.000648	CcSEcCtD
Gadoversetamide—Haemorrhage—Epirubicin—urinary bladder cancer	0.000647	0.000647	CcSEcCtD
Gadoversetamide—Eye disorder—Methotrexate—urinary bladder cancer	0.000646	0.000646	CcSEcCtD
Gadoversetamide—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000646	0.000646	CcSEcCtD
Gadoversetamide—Tinnitus—Methotrexate—urinary bladder cancer	0.000645	0.000645	CcSEcCtD
Gadoversetamide—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000644	0.000644	CcSEcCtD
Gadoversetamide—Asthenia—Cisplatin—urinary bladder cancer	0.000642	0.000642	CcSEcCtD
Gadoversetamide—Pharyngitis—Epirubicin—urinary bladder cancer	0.000642	0.000642	CcSEcCtD
Gadoversetamide—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000642	0.000642	CcSEcCtD
Gadoversetamide—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000639	0.000639	CcSEcCtD
Gadoversetamide—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000637	0.000637	CcSEcCtD
Gadoversetamide—Haematuria—Doxorubicin—urinary bladder cancer	0.000636	0.000636	CcSEcCtD
Gadoversetamide—Urethral disorder—Epirubicin—urinary bladder cancer	0.000634	0.000634	CcSEcCtD
Gadoversetamide—Epistaxis—Doxorubicin—urinary bladder cancer	0.000629	0.000629	CcSEcCtD
Gadoversetamide—Angiopathy—Methotrexate—urinary bladder cancer	0.000627	0.000627	CcSEcCtD
Gadoversetamide—Sinusitis—Doxorubicin—urinary bladder cancer	0.000626	0.000626	CcSEcCtD
Gadoversetamide—Immune system disorder—Methotrexate—urinary bladder cancer	0.000624	0.000624	CcSEcCtD
Gadoversetamide—Dizziness—Fluorouracil—urinary bladder cancer	0.000624	0.000624	CcSEcCtD
Gadoversetamide—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000623	0.000623	CcSEcCtD
Gadoversetamide—Chills—Methotrexate—urinary bladder cancer	0.00062	0.00062	CcSEcCtD
Gadoversetamide—Diarrhoea—Cisplatin—urinary bladder cancer	0.000612	0.000612	CcSEcCtD
Gadoversetamide—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000612	0.000612	CcSEcCtD
Gadoversetamide—Vomiting—Gemcitabine—urinary bladder cancer	0.000611	0.000611	CcSEcCtD
Gadoversetamide—Mental disorder—Methotrexate—urinary bladder cancer	0.000606	0.000606	CcSEcCtD
Gadoversetamide—Rash—Gemcitabine—urinary bladder cancer	0.000606	0.000606	CcSEcCtD
Gadoversetamide—Dermatitis—Gemcitabine—urinary bladder cancer	0.000605	0.000605	CcSEcCtD
Gadoversetamide—Eye disorder—Epirubicin—urinary bladder cancer	0.000605	0.000605	CcSEcCtD
Gadoversetamide—Hypersensitivity—Etoposide—urinary bladder cancer	0.000604	0.000604	CcSEcCtD
Gadoversetamide—Tinnitus—Epirubicin—urinary bladder cancer	0.000603	0.000603	CcSEcCtD
Gadoversetamide—Erythema—Methotrexate—urinary bladder cancer	0.000602	0.000602	CcSEcCtD
Gadoversetamide—Malnutrition—Methotrexate—urinary bladder cancer	0.000602	0.000602	CcSEcCtD
Gadoversetamide—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000602	0.000602	CcSEcCtD
Gadoversetamide—Headache—Gemcitabine—urinary bladder cancer	0.000602	0.000602	CcSEcCtD
Gadoversetamide—Cardiac disorder—Epirubicin—urinary bladder cancer	0.0006	0.0006	CcSEcCtD
Gadoversetamide—Flushing—Epirubicin—urinary bladder cancer	0.0006	0.0006	CcSEcCtD
Gadoversetamide—Vomiting—Fluorouracil—urinary bladder cancer	0.0006	0.0006	CcSEcCtD
Gadoversetamide—Rhinitis—Doxorubicin—urinary bladder cancer	0.0006	0.0006	CcSEcCtD
Gadoversetamide—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000599	0.000599	CcSEcCtD
Gadoversetamide—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000596	0.000596	CcSEcCtD
Gadoversetamide—Rash—Fluorouracil—urinary bladder cancer	0.000595	0.000595	CcSEcCtD
Gadoversetamide—Dermatitis—Fluorouracil—urinary bladder cancer	0.000595	0.000595	CcSEcCtD
Gadoversetamide—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000594	0.000594	CcSEcCtD
Gadoversetamide—Headache—Fluorouracil—urinary bladder cancer	0.000592	0.000592	CcSEcCtD
Gadoversetamide—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000591	0.000591	CcSEcCtD
Gadoversetamide—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.00059	0.00059	CcSEcCtD
Gadoversetamide—Dysgeusia—Methotrexate—urinary bladder cancer	0.000589	0.000589	CcSEcCtD
Gadoversetamide—Asthenia—Etoposide—urinary bladder cancer	0.000588	0.000588	CcSEcCtD
Gadoversetamide—Angiopathy—Epirubicin—urinary bladder cancer	0.000587	0.000587	CcSEcCtD
Gadoversetamide—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000587	0.000587	CcSEcCtD
Gadoversetamide—Immune system disorder—Epirubicin—urinary bladder cancer	0.000584	0.000584	CcSEcCtD
Gadoversetamide—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000583	0.000583	CcSEcCtD
Gadoversetamide—Back pain—Methotrexate—urinary bladder cancer	0.000582	0.000582	CcSEcCtD
Gadoversetamide—Chills—Epirubicin—urinary bladder cancer	0.000581	0.000581	CcSEcCtD
Gadoversetamide—Pruritus—Etoposide—urinary bladder cancer	0.00058	0.00058	CcSEcCtD
Gadoversetamide—Arrhythmia—Epirubicin—urinary bladder cancer	0.000578	0.000578	CcSEcCtD
Gadoversetamide—Nausea—Gemcitabine—urinary bladder cancer	0.00057	0.00057	CcSEcCtD
Gadoversetamide—Vomiting—Cisplatin—urinary bladder cancer	0.000569	0.000569	CcSEcCtD
Gadoversetamide—Vision blurred—Methotrexate—urinary bladder cancer	0.000567	0.000567	CcSEcCtD
Gadoversetamide—Mental disorder—Epirubicin—urinary bladder cancer	0.000567	0.000567	CcSEcCtD
Gadoversetamide—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000566	0.000566	CcSEcCtD
Gadoversetamide—Rash—Cisplatin—urinary bladder cancer	0.000564	0.000564	CcSEcCtD
Gadoversetamide—Dermatitis—Cisplatin—urinary bladder cancer	0.000564	0.000564	CcSEcCtD
Gadoversetamide—Malnutrition—Epirubicin—urinary bladder cancer	0.000563	0.000563	CcSEcCtD
Gadoversetamide—Erythema—Epirubicin—urinary bladder cancer	0.000563	0.000563	CcSEcCtD
Gadoversetamide—Diarrhoea—Etoposide—urinary bladder cancer	0.000561	0.000561	CcSEcCtD
Gadoversetamide—Nausea—Fluorouracil—urinary bladder cancer	0.000561	0.000561	CcSEcCtD
Gadoversetamide—Eye disorder—Doxorubicin—urinary bladder cancer	0.000559	0.000559	CcSEcCtD
Gadoversetamide—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000558	0.000558	CcSEcCtD
Gadoversetamide—Tinnitus—Doxorubicin—urinary bladder cancer	0.000558	0.000558	CcSEcCtD
Gadoversetamide—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000556	0.000556	CcSEcCtD
Gadoversetamide—Flushing—Doxorubicin—urinary bladder cancer	0.000556	0.000556	CcSEcCtD
Gadoversetamide—Flatulence—Epirubicin—urinary bladder cancer	0.000555	0.000555	CcSEcCtD
Gadoversetamide—Tension—Epirubicin—urinary bladder cancer	0.000553	0.000553	CcSEcCtD
Gadoversetamide—Dysgeusia—Epirubicin—urinary bladder cancer	0.000552	0.000552	CcSEcCtD
Gadoversetamide—Nervousness—Epirubicin—urinary bladder cancer	0.000547	0.000547	CcSEcCtD
Gadoversetamide—Back pain—Epirubicin—urinary bladder cancer	0.000545	0.000545	CcSEcCtD
Gadoversetamide—Angiopathy—Doxorubicin—urinary bladder cancer	0.000543	0.000543	CcSEcCtD
Gadoversetamide—Malaise—Methotrexate—urinary bladder cancer	0.000543	0.000543	CcSEcCtD
Gadoversetamide—Dizziness—Etoposide—urinary bladder cancer	0.000542	0.000542	CcSEcCtD
Gadoversetamide—Muscle spasms—Epirubicin—urinary bladder cancer	0.000542	0.000542	CcSEcCtD
Gadoversetamide—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000541	0.000541	CcSEcCtD
Gadoversetamide—Vertigo—Methotrexate—urinary bladder cancer	0.000541	0.000541	CcSEcCtD
Gadoversetamide—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.00054	0.00054	CcSEcCtD
Gadoversetamide—Chills—Doxorubicin—urinary bladder cancer	0.000537	0.000537	CcSEcCtD
Gadoversetamide—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000535	0.000535	CcSEcCtD
Gadoversetamide—Nausea—Cisplatin—urinary bladder cancer	0.000532	0.000532	CcSEcCtD
Gadoversetamide—Vision blurred—Epirubicin—urinary bladder cancer	0.000531	0.000531	CcSEcCtD
Gadoversetamide—Cough—Methotrexate—urinary bladder cancer	0.000525	0.000525	CcSEcCtD
Gadoversetamide—Mental disorder—Doxorubicin—urinary bladder cancer	0.000525	0.000525	CcSEcCtD
Gadoversetamide—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000523	0.000523	CcSEcCtD
Gadoversetamide—Convulsion—Methotrexate—urinary bladder cancer	0.000521	0.000521	CcSEcCtD
Gadoversetamide—Vomiting—Etoposide—urinary bladder cancer	0.000521	0.000521	CcSEcCtD
Gadoversetamide—Malnutrition—Doxorubicin—urinary bladder cancer	0.000521	0.000521	CcSEcCtD
Gadoversetamide—Erythema—Doxorubicin—urinary bladder cancer	0.000521	0.000521	CcSEcCtD
Gadoversetamide—Agitation—Epirubicin—urinary bladder cancer	0.000518	0.000518	CcSEcCtD
Gadoversetamide—Rash—Etoposide—urinary bladder cancer	0.000517	0.000517	CcSEcCtD
Gadoversetamide—Dermatitis—Etoposide—urinary bladder cancer	0.000517	0.000517	CcSEcCtD
Gadoversetamide—Headache—Etoposide—urinary bladder cancer	0.000514	0.000514	CcSEcCtD
Gadoversetamide—Flatulence—Doxorubicin—urinary bladder cancer	0.000514	0.000514	CcSEcCtD
Gadoversetamide—Chest pain—Methotrexate—urinary bladder cancer	0.000512	0.000512	CcSEcCtD
Gadoversetamide—Arthralgia—Methotrexate—urinary bladder cancer	0.000512	0.000512	CcSEcCtD
Gadoversetamide—Myalgia—Methotrexate—urinary bladder cancer	0.000512	0.000512	CcSEcCtD
Gadoversetamide—Tension—Doxorubicin—urinary bladder cancer	0.000511	0.000511	CcSEcCtD
Gadoversetamide—Dysgeusia—Doxorubicin—urinary bladder cancer	0.00051	0.00051	CcSEcCtD
Gadoversetamide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000509	0.000509	CcSEcCtD
Gadoversetamide—Malaise—Epirubicin—urinary bladder cancer	0.000508	0.000508	CcSEcCtD
Gadoversetamide—Discomfort—Methotrexate—urinary bladder cancer	0.000506	0.000506	CcSEcCtD
Gadoversetamide—Nervousness—Doxorubicin—urinary bladder cancer	0.000506	0.000506	CcSEcCtD
Gadoversetamide—Vertigo—Epirubicin—urinary bladder cancer	0.000506	0.000506	CcSEcCtD
Gadoversetamide—Syncope—Epirubicin—urinary bladder cancer	0.000505	0.000505	CcSEcCtD
Gadoversetamide—Back pain—Doxorubicin—urinary bladder cancer	0.000504	0.000504	CcSEcCtD
Gadoversetamide—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000501	0.000501	CcSEcCtD
Gadoversetamide—Palpitations—Epirubicin—urinary bladder cancer	0.000498	0.000498	CcSEcCtD
Gadoversetamide—Confusional state—Methotrexate—urinary bladder cancer	0.000495	0.000495	CcSEcCtD
Gadoversetamide—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000495	0.000495	CcSEcCtD
Gadoversetamide—Cough—Epirubicin—urinary bladder cancer	0.000492	0.000492	CcSEcCtD
Gadoversetamide—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000491	0.000491	CcSEcCtD
Gadoversetamide—Vision blurred—Doxorubicin—urinary bladder cancer	0.000491	0.000491	CcSEcCtD
Gadoversetamide—Convulsion—Epirubicin—urinary bladder cancer	0.000488	0.000488	CcSEcCtD
Gadoversetamide—Nausea—Etoposide—urinary bladder cancer	0.000487	0.000487	CcSEcCtD
Gadoversetamide—Hypertension—Epirubicin—urinary bladder cancer	0.000486	0.000486	CcSEcCtD
Gadoversetamide—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000484	0.000484	CcSEcCtD
Gadoversetamide—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000482	0.000482	CcSEcCtD
Gadoversetamide—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000481	0.000481	CcSEcCtD
Gadoversetamide—Chest pain—Epirubicin—urinary bladder cancer	0.00048	0.00048	CcSEcCtD
Gadoversetamide—Arthralgia—Epirubicin—urinary bladder cancer	0.00048	0.00048	CcSEcCtD
Gadoversetamide—Myalgia—Epirubicin—urinary bladder cancer	0.00048	0.00048	CcSEcCtD
Gadoversetamide—Agitation—Doxorubicin—urinary bladder cancer	0.000479	0.000479	CcSEcCtD
Gadoversetamide—Anxiety—Epirubicin—urinary bladder cancer	0.000478	0.000478	CcSEcCtD
Gadoversetamide—Skin disorder—Methotrexate—urinary bladder cancer	0.000477	0.000477	CcSEcCtD
Gadoversetamide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000476	0.000476	CcSEcCtD
Gadoversetamide—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000475	0.000475	CcSEcCtD
Gadoversetamide—Discomfort—Epirubicin—urinary bladder cancer	0.000474	0.000474	CcSEcCtD
Gadoversetamide—Malaise—Doxorubicin—urinary bladder cancer	0.00047	0.00047	CcSEcCtD
Gadoversetamide—Dry mouth—Epirubicin—urinary bladder cancer	0.000469	0.000469	CcSEcCtD
Gadoversetamide—Vertigo—Doxorubicin—urinary bladder cancer	0.000468	0.000468	CcSEcCtD
Gadoversetamide—Anorexia—Methotrexate—urinary bladder cancer	0.000468	0.000468	CcSEcCtD
Gadoversetamide—Syncope—Doxorubicin—urinary bladder cancer	0.000467	0.000467	CcSEcCtD
Gadoversetamide—Confusional state—Epirubicin—urinary bladder cancer	0.000464	0.000464	CcSEcCtD
Gadoversetamide—Palpitations—Doxorubicin—urinary bladder cancer	0.000461	0.000461	CcSEcCtD
Gadoversetamide—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.00046	0.00046	CcSEcCtD
Gadoversetamide—Oedema—Epirubicin—urinary bladder cancer	0.00046	0.00046	CcSEcCtD
Gadoversetamide—Hypotension—Methotrexate—urinary bladder cancer	0.000459	0.000459	CcSEcCtD
Gadoversetamide—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000458	0.000458	CcSEcCtD
Gadoversetamide—Cough—Doxorubicin—urinary bladder cancer	0.000455	0.000455	CcSEcCtD
Gadoversetamide—Shock—Epirubicin—urinary bladder cancer	0.000452	0.000452	CcSEcCtD
Gadoversetamide—Convulsion—Doxorubicin—urinary bladder cancer	0.000452	0.000452	CcSEcCtD
Gadoversetamide—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000451	0.000451	CcSEcCtD
Gadoversetamide—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.00045	0.00045	CcSEcCtD
Gadoversetamide—Hypertension—Doxorubicin—urinary bladder cancer	0.00045	0.00045	CcSEcCtD
Gadoversetamide—Tachycardia—Epirubicin—urinary bladder cancer	0.000449	0.000449	CcSEcCtD
Gadoversetamide—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000448	0.000448	CcSEcCtD
Gadoversetamide—Skin disorder—Epirubicin—urinary bladder cancer	0.000447	0.000447	CcSEcCtD
Gadoversetamide—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000444	0.000444	CcSEcCtD
Gadoversetamide—Insomnia—Methotrexate—urinary bladder cancer	0.000444	0.000444	CcSEcCtD
Gadoversetamide—Arthralgia—Doxorubicin—urinary bladder cancer	0.000444	0.000444	CcSEcCtD
Gadoversetamide—Chest pain—Doxorubicin—urinary bladder cancer	0.000444	0.000444	CcSEcCtD
Gadoversetamide—Myalgia—Doxorubicin—urinary bladder cancer	0.000444	0.000444	CcSEcCtD
Gadoversetamide—Anxiety—Doxorubicin—urinary bladder cancer	0.000442	0.000442	CcSEcCtD
Gadoversetamide—Paraesthesia—Methotrexate—urinary bladder cancer	0.000441	0.000441	CcSEcCtD
Gadoversetamide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000441	0.000441	CcSEcCtD
Gadoversetamide—Discomfort—Doxorubicin—urinary bladder cancer	0.000438	0.000438	CcSEcCtD
Gadoversetamide—Anorexia—Epirubicin—urinary bladder cancer	0.000438	0.000438	CcSEcCtD
Gadoversetamide—Dyspnoea—Methotrexate—urinary bladder cancer	0.000438	0.000438	CcSEcCtD
Gadoversetamide—Somnolence—Methotrexate—urinary bladder cancer	0.000437	0.000437	CcSEcCtD
Gadoversetamide—Dry mouth—Doxorubicin—urinary bladder cancer	0.000434	0.000434	CcSEcCtD
Gadoversetamide—Dyspepsia—Methotrexate—urinary bladder cancer	0.000432	0.000432	CcSEcCtD
Gadoversetamide—Hypotension—Epirubicin—urinary bladder cancer	0.00043	0.00043	CcSEcCtD
Gadoversetamide—Confusional state—Doxorubicin—urinary bladder cancer	0.000429	0.000429	CcSEcCtD
Gadoversetamide—Decreased appetite—Methotrexate—urinary bladder cancer	0.000427	0.000427	CcSEcCtD
Gadoversetamide—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000425	0.000425	CcSEcCtD
Gadoversetamide—Oedema—Doxorubicin—urinary bladder cancer	0.000425	0.000425	CcSEcCtD
Gadoversetamide—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000424	0.000424	CcSEcCtD
Gadoversetamide—Fatigue—Methotrexate—urinary bladder cancer	0.000423	0.000423	CcSEcCtD
Gadoversetamide—Pain—Methotrexate—urinary bladder cancer	0.00042	0.00042	CcSEcCtD
Gadoversetamide—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000419	0.000419	CcSEcCtD
Gadoversetamide—Shock—Doxorubicin—urinary bladder cancer	0.000418	0.000418	CcSEcCtD
Gadoversetamide—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000417	0.000417	CcSEcCtD
Gadoversetamide—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000416	0.000416	CcSEcCtD
Gadoversetamide—Insomnia—Epirubicin—urinary bladder cancer	0.000416	0.000416	CcSEcCtD
Gadoversetamide—Tachycardia—Doxorubicin—urinary bladder cancer	0.000415	0.000415	CcSEcCtD
Gadoversetamide—Skin disorder—Doxorubicin—urinary bladder cancer	0.000413	0.000413	CcSEcCtD
Gadoversetamide—Paraesthesia—Epirubicin—urinary bladder cancer	0.000413	0.000413	CcSEcCtD
Gadoversetamide—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000411	0.000411	CcSEcCtD
Gadoversetamide—Dyspnoea—Epirubicin—urinary bladder cancer	0.00041	0.00041	CcSEcCtD
Gadoversetamide—Somnolence—Epirubicin—urinary bladder cancer	0.000409	0.000409	CcSEcCtD
Gadoversetamide—Anorexia—Doxorubicin—urinary bladder cancer	0.000405	0.000405	CcSEcCtD
Gadoversetamide—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000405	0.000405	CcSEcCtD
Gadoversetamide—Dyspepsia—Epirubicin—urinary bladder cancer	0.000405	0.000405	CcSEcCtD
Gadoversetamide—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000402	0.000402	CcSEcCtD
Gadoversetamide—Decreased appetite—Epirubicin—urinary bladder cancer	0.0004	0.0004	CcSEcCtD
Gadoversetamide—Hypotension—Doxorubicin—urinary bladder cancer	0.000397	0.000397	CcSEcCtD
Gadoversetamide—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000397	0.000397	CcSEcCtD
Gadoversetamide—Fatigue—Epirubicin—urinary bladder cancer	0.000396	0.000396	CcSEcCtD
Gadoversetamide—Pain—Epirubicin—urinary bladder cancer	0.000393	0.000393	CcSEcCtD
Gadoversetamide—Constipation—Epirubicin—urinary bladder cancer	0.000393	0.000393	CcSEcCtD
Gadoversetamide—Urticaria—Methotrexate—urinary bladder cancer	0.00039	0.00039	CcSEcCtD
Gadoversetamide—Body temperature increased—Methotrexate—urinary bladder cancer	0.000388	0.000388	CcSEcCtD
Gadoversetamide—Abdominal pain—Methotrexate—urinary bladder cancer	0.000388	0.000388	CcSEcCtD
Gadoversetamide—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000388	0.000388	CcSEcCtD
Gadoversetamide—Insomnia—Doxorubicin—urinary bladder cancer	0.000385	0.000385	CcSEcCtD
Gadoversetamide—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000382	0.000382	CcSEcCtD
Gadoversetamide—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000379	0.000379	CcSEcCtD
Gadoversetamide—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000379	0.000379	CcSEcCtD
Gadoversetamide—Somnolence—Doxorubicin—urinary bladder cancer	0.000378	0.000378	CcSEcCtD
Gadoversetamide—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000376	0.000376	CcSEcCtD
Gadoversetamide—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000374	0.000374	CcSEcCtD
Gadoversetamide—Decreased appetite—Doxorubicin—urinary bladder cancer	0.00037	0.00037	CcSEcCtD
Gadoversetamide—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000367	0.000367	CcSEcCtD
Gadoversetamide—Fatigue—Doxorubicin—urinary bladder cancer	0.000367	0.000367	CcSEcCtD
Gadoversetamide—Urticaria—Epirubicin—urinary bladder cancer	0.000365	0.000365	CcSEcCtD
Gadoversetamide—Pain—Doxorubicin—urinary bladder cancer	0.000364	0.000364	CcSEcCtD
Gadoversetamide—Constipation—Doxorubicin—urinary bladder cancer	0.000364	0.000364	CcSEcCtD
Gadoversetamide—Abdominal pain—Epirubicin—urinary bladder cancer	0.000363	0.000363	CcSEcCtD
Gadoversetamide—Body temperature increased—Epirubicin—urinary bladder cancer	0.000363	0.000363	CcSEcCtD
Gadoversetamide—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000362	0.000362	CcSEcCtD
Gadoversetamide—Asthenia—Methotrexate—urinary bladder cancer	0.000352	0.000352	CcSEcCtD
Gadoversetamide—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000351	0.000351	CcSEcCtD
Gadoversetamide—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000348	0.000348	CcSEcCtD
Gadoversetamide—Pruritus—Methotrexate—urinary bladder cancer	0.000348	0.000348	CcSEcCtD
Gadoversetamide—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000339	0.000339	CcSEcCtD
Gadoversetamide—Urticaria—Doxorubicin—urinary bladder cancer	0.000338	0.000338	CcSEcCtD
Gadoversetamide—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000336	0.000336	CcSEcCtD
Gadoversetamide—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000336	0.000336	CcSEcCtD
Gadoversetamide—Diarrhoea—Methotrexate—urinary bladder cancer	0.000336	0.000336	CcSEcCtD
Gadoversetamide—Asthenia—Epirubicin—urinary bladder cancer	0.00033	0.00033	CcSEcCtD
Gadoversetamide—Pruritus—Epirubicin—urinary bladder cancer	0.000325	0.000325	CcSEcCtD
Gadoversetamide—Dizziness—Methotrexate—urinary bladder cancer	0.000325	0.000325	CcSEcCtD
Gadoversetamide—Diarrhoea—Epirubicin—urinary bladder cancer	0.000315	0.000315	CcSEcCtD
Gadoversetamide—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000313	0.000313	CcSEcCtD
Gadoversetamide—Vomiting—Methotrexate—urinary bladder cancer	0.000312	0.000312	CcSEcCtD
Gadoversetamide—Rash—Methotrexate—urinary bladder cancer	0.00031	0.00031	CcSEcCtD
Gadoversetamide—Dermatitis—Methotrexate—urinary bladder cancer	0.000309	0.000309	CcSEcCtD
Gadoversetamide—Headache—Methotrexate—urinary bladder cancer	0.000308	0.000308	CcSEcCtD
Gadoversetamide—Asthenia—Doxorubicin—urinary bladder cancer	0.000305	0.000305	CcSEcCtD
Gadoversetamide—Dizziness—Epirubicin—urinary bladder cancer	0.000304	0.000304	CcSEcCtD
Gadoversetamide—Pruritus—Doxorubicin—urinary bladder cancer	0.000301	0.000301	CcSEcCtD
Gadoversetamide—Vomiting—Epirubicin—urinary bladder cancer	0.000292	0.000292	CcSEcCtD
Gadoversetamide—Nausea—Methotrexate—urinary bladder cancer	0.000292	0.000292	CcSEcCtD
Gadoversetamide—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000291	0.000291	CcSEcCtD
Gadoversetamide—Rash—Epirubicin—urinary bladder cancer	0.00029	0.00029	CcSEcCtD
Gadoversetamide—Dermatitis—Epirubicin—urinary bladder cancer	0.00029	0.00029	CcSEcCtD
Gadoversetamide—Headache—Epirubicin—urinary bladder cancer	0.000288	0.000288	CcSEcCtD
Gadoversetamide—Dizziness—Doxorubicin—urinary bladder cancer	0.000281	0.000281	CcSEcCtD
Gadoversetamide—Nausea—Epirubicin—urinary bladder cancer	0.000273	0.000273	CcSEcCtD
Gadoversetamide—Vomiting—Doxorubicin—urinary bladder cancer	0.00027	0.00027	CcSEcCtD
Gadoversetamide—Rash—Doxorubicin—urinary bladder cancer	0.000268	0.000268	CcSEcCtD
Gadoversetamide—Dermatitis—Doxorubicin—urinary bladder cancer	0.000268	0.000268	CcSEcCtD
Gadoversetamide—Headache—Doxorubicin—urinary bladder cancer	0.000266	0.000266	CcSEcCtD
Gadoversetamide—Nausea—Doxorubicin—urinary bladder cancer	0.000253	0.000253	CcSEcCtD
